Translational Psychiatry Q1区

期刊简介

Psychiatry has suffered tremendously by the limited translational pipeline. Nobel laureate Julius Axelrod's discovery in 1961 of monoamine reuptake by pre-synaptic neurons still forms the basis of contemporary antidepressant treatment. There is a grievous gap between the explosion of knowledge in neuroscience and conceptually novel treatments for our patients. Translational Psychiatry bridges this gap by fostering and highlighting the pathway from discovery to clinical applications, healthcare and global health. We view translation broadly as the full spectrum of work that marks the pathway from discovery to global health, inclusive. The steps of translation that are within the scope of Translational Psychiatry include (i) fundamental discovery, (ii) bench to bedside, (iii) bedside to clinical applications (clinical trials), (iv) translation to policy and health care guidelines, (v) assessment of health policy and usage, and (vi) global health. All areas of medical research, including — but not restricted to — molecular biology, genetics, pharmacology, imaging and epidemiology are welcome as they contribute to enhance the field of translational psychiatry.

有限的翻译渠道给精神病学带来了巨大的损失。诺贝尔奖得主Julius Axelrod在1961年发现突触前神经元重摄取单胺，这一发现至今仍是当代抗抑郁治疗的基础。在神经科学知识的爆炸式增长和为我们的病人提供概念上的新疗法之间存在着严重的差距。转化精神病学通过促进和强调从发现到临床应用、医疗保健和全球健康的途径来弥合这一差距。我们将翻译广泛地视为从发现到全球健康的全方位工作。转化精神病学范围内的转化步骤包括（i）基础发现，（ii）从实验室到床边，（iii）从床边到临床应用（临床试验），（iv）转化为政策和卫生保健指南，（v）评估卫生政策和使用，以及（vi）全球卫生。欢迎所有医学研究领域，包括但不限于分子生物学、遗传学、药理学、成像和流行病学，因为它们有助于加强转化精神病学领域。

《Translational Psychiatry》期刊已被查看： 次

期刊官网投稿信息

分区信息

• 上一篇： Flora Montiberica
• 下一篇：Erudition and the Republic of Letters